Dec 16, 2021 06:32AM moderators wrote:

Aromatase Inhibitors versus Tamoxifen for Pre-Menopausal Women Diagnosed With Early-Stage, Hormone Receptor-Positive Disease

December 13, 2021

Dr. Jeremy Braybrooke, is a consultant medical oncologist and clinical lead for oncology at University Hospitals Bristol, as well as a senior clinical research fellow at the University of Oxford. Rosie Bradley is a medical statistician in the Clinical Trial Service Unit at the University of Oxford.

At the 2021 San Antonio Breast Cancer Symposium, Rosie presented the results of their meta-analysis of four studies looking at effectiveness of aromatase inhibitors compared to tamoxifen in pre-menopausal women diagnosed with early-stage, hormone receptor-positive disease.

Listen to the episode to hear them explain:

• the results of the study, showing that an aromatase inhibitor and ovarian suppression reduced recurrence risk more than tamoxifen, but didn't lead to better overall survival
• the side effects of aromatase inhibitors and tamoxifen
• how Dr. Braybrooke is advising his pre-menopausal patients diagnosed with early-stage, hormone receptor-positive disease

Running time: 14:19

May 10, 2022 09:36AM moderators wrote:

Adolescent and Young Adult Breast Cancer

March 28, 2022

Rebecca Johnson, MD, discusses issues that are more challenging for younger women with breast cancer, reconstruction considerations for young women, and her advice for a newly diagnosed adolescent or young woman.

Listen to the episode to hear Dr. Johnson discuss:

* why the number of younger women diagnosed with breast cancer is going up, as well as the size of the increase
* issues that are more challenging for younger women with breast cancer reconstruction
* options for very young women
* her advice for a newly diagnosed adolescent or young woman

Running time: 52:45